# Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS Study

> **NCT04381091** · — · NO_LONGER_AVAILABLE · sponsor: **Santhera Pharmaceuticals**

## Conditions studied

- Leber's Hereditary Optic Neuropathy

## Interventions

- **DRUG:** Idebenone 150 MG Oral Tablet

## Key facts

- **NCT ID:** NCT04381091
- **Lead sponsor:** Santhera Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2023-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04381091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04381091, "Expanded Access Program for Idebenone in Patients With Leber's Hereditary Optic Neuropathy Who Completed the LEROS Study". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04381091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*